Targets › IFNA
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease.
Open in Phaseline: the race on IFNA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Third Affiliated Hospital, Sun Yat-Sen University | pegylated interferon-alfa Type I interferon receptor agonist with antiviral and immunomodulatory properties for hepa | IFNA | Phase 4 | Hepatitis B, Chronic | – |
Hepatitis B, Chronic (1)
protein or peptide (1)
Third Affiliated Hospital, Sun Yat-Sen University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.